Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Charles Gersbach
Duke University, Department: Biomedical Engineering
Should you be removed from our database? Contact us at [email protected]. Read more below.
Sarepta Therapeutics, Inc.
Payment for services (e.g., consulting fees, honoraria, paid authorship)
Sarepta is involved in developing treatments for patients with Duchenne muscular dystrophy (DMD).
CRISPR/Cas9-Based Gene Editing for the Correction of Duchenne Muscular Dystrophy
PUBLIC HEALTH RELEVANCE Gene therapy holds incredible potential for curing inherited diseases, including neuromuscular disorders. However, the potential of gene therapy has not been realized due to fundamental limitations of gene delivery technologies. This project uses an innovative approach to correct the disease-causing genetic mutations, rather than delivering extra genes, as a therapy for Duchenne Muscular Dystrophy.
Filed on December 21, 2017.
Tell us what you know about Charles Gersbach's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Charles Gersbach filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Charles Gersbach | Duke University | Conflict of Interest | Editas Medicine | $200,000 - $249,999 |
| Charles Gersbach | Duke University | Conflict of Interest | Editas Medicine | $20,000 - $39,999 |
| Charles Gersbach | Duke University | Conflict of Interest | Element Genomics, Inc. | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.